Johnson & Johnson Subsidiary Files for Bankruptcy for the Third Time, Aiming to Shed $100 Billion in Debt, Thousands of Cancer Patients Left Without Recourse!
A unit of Johnson & Johnson filed for bankruptcy Wednesday for the third time, Reuters reported, aiming to advance a $10 billion settlement to end tens of thousands of lawsuits alleging the company's baby powder and other talc products may cause cancer.
More than 62,000 plaintiffs have claimed that Johnson's baby powder and other talc products are contaminated and that they cause ovarian cancer and other types of cancer. In response to the lawsuits, J&J's subsidiary, Red River Talc, has filed for bankruptcy protection in federal bankruptcy court in Houston.
Erik Haas, Johnson & Johnson's vice president of global litigation, said the settlement was "fair and reasonable for all parties," noting that 83 percent of claimants have now supported it.
However, the proposed settlement has sparked controversy among a group of lawyers representing cancer victims. Some opponents said they would move quickly to ask the court to dismiss J&J's bankruptcy filing or have it moved to New Jersey. New Jersey courts have twice rejected J&J's attempts to end litigation through a so-called "Texas two-step" bankruptcy strategy.
Andy Birchfield, a lawyer who opposed the deal, pointed out that Johnson & Johnson is trying to use the bankruptcy system to reduce its liability to tens of thousands of cancer patients.
The report further explained that the "two-step" strategy used by J&J involved transferring debt to a newly formed subsidiary, which subsequently declared bankruptcy. This is a court-supervised asset and debt restructuring process designed to force all plaintiffs to accept a settlement.
2026-10-09
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Terminates Anti-Dumping Investigation on Chinese Siloxane Polyoxyalkylene Copolymers
-
INEOS Plant Closures Deepen Europe’s Chemical Industry Crisis
-
Dow Chemical’s Freeport Plant Fire Contained; No Injuries Reported
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
Dow Europe Raises Polyurethane Prices in EMEA and India
-
BASF-Evonik Takeover Faces Political Resistance as German State Defends Jobs and Independence
-
$1.35 Billion! AkzoNobel to Sell Decorative Paints Business in Southeast Asia and Australia to Nippon Paint
-
Sinopec and CNAF to Implement Restructuring
Recommend Reading
-
INEOS Closes US Polystrene Plant: 400K Tons of PD in the US Can't Hold On
-
Evonik Cuts 3,200 Jobs: Europe’s Chemical Winter Is Not Over
-
Evonik Restructures Strategic R&D and Aims to Move Projects into Application Within Five Years
-
Korea’s Antitrust Probe Targets Coatings Price Hikes as Five Major Players Come Under Investigation
-
India Removes Import Tax on 40 Petrochemical Products
-
The Game Between Supply and Demand Tends Toward Equilibrium; Formic Acid Ranges Sideways
-
Both Supply and Demand Weak & Inventory Pressures Keep PVC Market Volatile and Tend to Be Weak
-
This Round Sees the First Retail Price Drop for Refined Oil Products This Year
-
Business Society’s DOP Trend Analysis on September 14, 2026: Strongly Bullish
-
Positive Factors Support Rising Coking Coal Prices